Navigation Links
1st EMEA application filed for product using innovative intradermal microinjection system BD Soluvia
Date:2/13/2008

Franklin Lakes, NJ, USA (February 13, 2008) -- Sanofi Pasteur, the vaccines division of sanofi-aventis Group, has submitted the first application in Europe to deliver a vaccine using BD Soluvia, the innovative microinjection system developed by BD (Becton, Dickinson and Company). The submission for the first influenza vaccine using BD Soluvia has been accepted for review by the European Medicines Agency (EMEA).

Sanofi Pasteur conducted clinical trials on more than 7000 subjects to evaluate safety and the ability to generate an immune response of the novel intradermal (ID) influenza vaccine. Compared with intramuscular (IM) injection, ID delivery was shown to be especially effective in enhancing the immune response in the elderly1,2. Independently, BD conducted clinical trials involving more than 700 subjects and 3500 injections with BD Soluvia, and demonstrated that the system was safe and easy to use.3. Clinical testing showed that the BD microneedle is barely perceptible when it enters the skin and ensures the administration of the injected solution to the dermal layer irrespective of the subject s gender, age, ethnicity and body mass.4

BD Soluvia is a prefillable microinjection system that is integrated with a tiny BD microneedle. It has been proven to offer a simple, reliable method of delivery. While most vaccines are injected into the muscle, the BD microneedle allows the vaccine to be accurately delivered intradermally -- within the dermal layer of the skin. The dermal layer contains a dense network of lymphatic vessels feeding local lymph nodes, resulting in rapid and efficient access of the vaccine into the immune system. It also contains a high concentration of potent immune cells that play a key role to initiate the immune response following vaccination.

BD is committed to developing innovative solutions to advance drug delivery with pharmaceutical companies, and to meet the needs of healthcare professionals, said Philippe Laurent, Vice President, Medical Affairs, BD Medical V Pharmaceutical Systems. The BD Soluvia microinjection system is a breakthrough technology that is intuitive to use and allows accurate and consistent delivery of substances such as the flu vaccine into the dermal layer. We believe it has the potential to help address some of the important health challenges facing the world today, and embodies BD s purpose of helping all people live healthy lives.

We are delighted to have reached this landmark in development with our partner, sanofi pasteur, said Alex Conroy, President, BD Medical - Pharmaceutical Systems. In practical terms, the BD Soluvia microinjection system has the potential to increase patients acceptance of injections and enhance immunization practices. BD is deeply committed to continuing the development of BD Soluvia for the intradermal route of administration for use with infectious disease and emerging cancer vaccines.


'/>"/>
Contact: Alyssa Zeff
Alyssa_Zeff@bd.com
201-847-4358
Ruder Finn Public Relations
Source:Eurekalert

Related medicine news :

1. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
2. Investigational New Drug Application for Fat Melting Injections Cleared by the FDA
3. PreMD Provides Update on 510(k) Application for PREVU(x) POC
4. Mindray Selects Actel Low-Power Flash FPGAs for Demanding Medical Equipment Applications
5. Medical Services International Inc. Completes Testing for European Union (EU) Application
6. Pharsight Files Application for Nasdaq Capital Market Listing
7. PartsSource Awarded US Patent for PartsFinder(TM) Application
8. HealthCentral.com Launches Greeting Card Application on Facebook.com
9. FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125
10. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
11. FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2017)... ... ... KICKICO , a protocol built on Ethereum for more transparent ICO ... within funding campaigns. KICKICO developers are testing the platform, which will launch for the ... funds through the power of many - has been around for about ten years ...
(Date:6/25/2017)... ... , ... FCPX LUT Vintage Volume 2 for Final Cut Pro X allows ... 2 contains 60 different color-grade presets, giving editors multiple options for adding different color ... out subjects, plus much more. FCPX LUT Vintage Volume 2 is designed for any ...
(Date:6/25/2017)... ... 25, 2017 , ... Republicans in the United States Senate on Thursday released ... Care Reconciliation Act. It differs significantly from the American Health Care Act, which the ... committee, or the House will have to take up the Senate version as-is, if ...
(Date:6/25/2017)... ... , ... CareSet Labs released the Root NPI Graph today at the 2017 ... improved version of the Doctor Referral teaming dataset commonly available from Medicare. , Originally ... the the “Doctor Referral Dataset” as released by Medicare and “DocGraph” as released by ...
(Date:6/25/2017)... ... ... Men’s Health Month and the focus is on prostate cancer. Second only to skin ... third most common cause of cancer related death today; lung cancer remains in the number ... prostate cancer during his lifetime. Those at highest risk are men who have ...
Breaking Medicine News(10 mins):
(Date:6/19/2017)... Pa. , June 19, 2017  Researchers from ... today that they will host a live, complimentary webinar ... from the benchtop to the real world" on Wednesday ... EDT. This webinar will feature interviews ... rare look into the manipulation techniques abusers use to ...
(Date:6/14/2017)... 2017  In 2016, Embodied Labs took ... competition and came away with $25,000 in seed-fund investment. ... Forbes as "entering the life of another" and by ... "empathy to medical professionals in an entirely new dimension." ... a finalist for the Department of Education,s EdSimChallenge, where ...
(Date:6/9/2017)... , June 9, 2017 AirXpanders, Inc. (ASX: ... on the design, manufacture, sale and distribution of the ... the progress of its commercial roll-out in ... in more than one hundred (100) medical institutions and ... AeroForm offers a needle-free alternative for women who choose ...
Breaking Medicine Technology: